COVID-19: The therapeutic landscape.
Journal
Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215
Informations de publication
Date de publication:
14 05 2021
14 05 2021
Historique:
pubmed:
27
4
2021
medline:
27
4
2021
entrez:
26
4
2021
Statut:
ppublish
Résumé
Therapeutics for hospitalized COVID-19 patients were identified through a robust research response with several lessons learned: clinical trial data should guide therapeutic use, results should not be extrapolated between disease stages, and robust studies should be designed to give clinically relevant data. These lessons should be applied to the outpatient research response.
Identifiants
pubmed: 33899041
doi: 10.1016/j.medj.2021.04.015
pii: S2666-6340(21)00164-1
pmc: PMC8057546
doi:
Types de publication
Journal Article
Langues
eng
Pagination
493-497Informations de copyright
© 2021 Elsevier Inc.
Déclaration de conflit d'intérêts
Dr. Fauci declares no competing interests. Dr. Paules is the site principal investigator at Penn State Health for The Adaptive Covid-19 Treatment Trial (ACTT), which receives funding from the National Institutes of Health.